Alethia BioTherapeutics
Alethia Biotherapeutics is a Montreal-based private biotechnology company focused on discovering and developing therapeutic monoclonal antibodies targeting highly specific, clinically relevant tissue targets. The company is engaged in clinical-stage research, with a focus on cancer and immunotherapy, utilizing proprietary technologies such as STAR for target discovery.
Industries
Nr. of Employees
small (1-50)
Alethia BioTherapeutics
141, avenue du Président-Kennedy, Bureau SB-5100, Montréal, Québec, CANADA H2X 1Y4
Patents
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US-9512211-B2
View DetailsAnti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US-8802826-B2
View Details
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US-9512211-B2
View DetailsAnti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US-8802826-B2
View DetailsProducts
Clinical-stage monoclonal antibody inhibiting epithelial-to-mesenchymal transition (targets secreted clusterin)
A humanized IgG2 monoclonal antibody that selectively binds and inhibits tumor-associated secreted clusterin, demonstrated in preclinical models to block or revert EMT, reduce tumor invasion, and increase response to chemotherapy; evaluated in Phase I and Phase II oncology trials (combination with docetaxel and with neoadjuvant FOLFOX).
Clinical-stage monoclonal antibody inhibiting epithelial-to-mesenchymal transition (targets secreted clusterin)
A humanized IgG2 monoclonal antibody that selectively binds and inhibits tumor-associated secreted clusterin, demonstrated in preclinical models to block or revert EMT, reduce tumor invasion, and increase response to chemotherapy; evaluated in Phase I and Phase II oncology trials (combination with docetaxel and with neoadjuvant FOLFOX).
Services
Target identification using a sensitive transcription-based subtractive amplification/representation approach to detect differentially expressed transcripts, including low-abundance mRNAs, for therapeutic target selection.
Design and execution of early- to mid-stage oncology clinical trials, including IND preparation, multicenter study conduct, combination therapy protocols, and clinical endpoint evaluation.
Target identification using a sensitive transcription-based subtractive amplification/representation approach to detect differentially expressed transcripts, including low-abundance mRNAs, for therapeutic target selection.
Design and execution of early- to mid-stage oncology clinical trials, including IND preparation, multicenter study conduct, combination therapy protocols, and clinical endpoint evaluation.
Expertise Areas
- Monoclonal antibody therapeutics development
- Functional genomics and subtractive transcription-based target discovery
- Preclinical in vivo cancer models (xenografts)
- Clinical trial management for oncology (Phase I/II)
Key Technologies
- Monoclonal antibody therapeutics
- Transcription-based subtractive amplification and representation for differential expression
- In vivo xenograft tumor models
- Neoadjuvant and combination chemotherapy clinical trial designs
News & Updates
Dr. Normand Blais, Dr. Mario Filion, Dr. Jacques Jolivet and Dr. Julie Laurin will present on a Phase II trial evaluating the EMT inhibitor Sotevtamab combined with Docetaxel in metastatic non-small cell lung cancer.
Dr. Mario Filion and Dr. Julie Laurin will present on a Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies.
Dr. Mario Filion presented on targeting EMT to treat advanced carcinomas with an anti-clusterin antibody.
Dr. Normand Blais, Dr. Mario Filion, Dr. Jacques Jolivet and Dr. Julie Laurin will present on a Phase II trial evaluating the EMT inhibitor Sotevtamab combined with Docetaxel in metastatic non-small cell lung cancer.
Dr. Mario Filion and Dr. Julie Laurin will present on a Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies.
Dr. Mario Filion presented on targeting EMT to treat advanced carcinomas with an anti-clusterin antibody.